Meglumine

Summary

Meglumine (CHEMBL1200570) is an approved small molecule; indicated across 4 conditions including mucocutaneous leishmaniasis and leishmaniasis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 4
• Chemistry: 195.21 Da · C7H17NO5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200570
Name	Meglumine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	8567
ChEBI	CHEBI:59732
Molecular formula	C7H17NO5
Molecular weight	195.21
InChIKey	MBBZMMPHUWSWHV-BDVNFPICSA-N

SMILES: CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O

IUPAC name: (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol

ChEBI definition: A hexosamine that is D-glucitol in which the hydroxy group at position 1 is substituted by the nitrogen of a methylamino group. A crystalline base, it is used in preparing salts of certain acids for use as diagnostic radiopaque media, while its antimonate is used as an antiprotozoal in the treatment of leishmaniasis.

Also known as: D(-)-n-methylglucamine, Meglumina, Meglumine, Megluminum, Methylglucamine, N-methylglucamine, N-methylsorbitylamine, NSC-52907, NSC-7391, MEGLUMINE, SID144205883, SID144212354

Patent coverage: 51,903 distinct patent families (183,992 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
mucocutaneous leishmaniasis	2	MONDO:0005859	EFO:0007379
leishmaniasis	2	MONDO:0011989	EFO:0005044

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE2	2
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06822478	PHASE3	RECRUITING	Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis II.
NCT00600548	PHASE2	COMPLETED	Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil)
NCT05147051	PHASE2	COMPLETED	Meglimine Sodium Succinate for Correction of Metabolic Acidosis in Critically Ill Patients
NCT00469495	Not specified	COMPLETED	Antihelminthic Therapy Combined With Antimony in the Treatment of Cutaneous Leishmaniasis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).